Devonian Health Group, Inc.

Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine(TM), with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Devonian Advances Thykamine(TM) Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Devonian reports additional molecular data from MASH liver study

DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY